Well I look at the fact that there have been a few high profile new stories in the last few years concerning the P53 gene and the important function it plays in cancer. The elephant story which went through the news cycles is likely one which I think most people will have paid attention. So it is definitely out in the universe for the lay-people (investors and patients alike) that P53 is important and playing a pivotal role in cancer. That's why I am surprised that CTIX has not received more coverage on it.
I just wish the Leo and Al could drive a PR campaign to spread the word of a drug which is "working" on the P53 gene. The main problem with that is then they will just be pegged as pumpers trying to drive the stock up. It is such a double edged sword: we need the third party medical validation to demonstrate to the investment community that it is the real deal, but the medical community will not dare validate until they see the concrete, conclusive evidence that it does work. Investors really just need someone of reputation to say that it most likely works and then they'll take on the risks and jump on board. The problem is that CTIX cant say it works because no one will believe it. BAH!!!! Were stuck in a open loop cycle here!!!!!